fbpx

Year

2020
Tre forskere fra Københavns Universitet har som de første vist, hvor i kroppen særlige ’fedmegener’ er aktive.  Hvorfor udvikler nogle mennesker fedme, mens andre tilsyneladende ubesværet opretholder en såkaldt normalvægt livet igennem? Spørgsmålet optager forskere verden over, og der er en lang række bud på, hvad ’motoren’ bag fedmeudvikling egentlig er, fortæller Tune H. Pers,...
Sibofimloc (EB8018/TAK-018) is a first-in-class, orally administered, gut-restricted small molecule designed to reduce inflammation underlying Crohn’s disease Sibofimloc binds FimH, a novel microbiome-derived therapeutic target validated by Enterome, to selectively disarm virulent bacteria in the gut that can cause inflammation without disrupting the local microbiome Sibofimloc is advancing through clinical development under a global licensing,...
– Data to be Presented at the ESMO Virtual Congress 2020 – Melanoma trial (MM1636) shows best-in-class efficacy data in first line melanoma of IO102 and IO103 in combination with nivolumab (anti-PD1 antibody) Copenhagen, Denmark – September 18, 2020: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology,...
Populærforestillingen om de blonde, ’skandinavisk udseende’ vikinger har fået en lige højre. For nogle vikinger var mørkhårede, andre leverpostejsfarvede. Vikingerne repræsenterede i virkeligheden en blandet genetik, som også havde sydeuropæiske og asiatiske rødder. Det dokumenterer en videnskabelig artikel i Nature. Artiklen er skrevet af et stort internationalt eksperthold under ledelse af Lundbeckfonden-forskere. Den tager samtidig...
Study Being Led by Leading Ocular Oncologist, Carol L. Shields, M.D., Director, Ocular Oncology Service, Wills Eye Hospital CAMBRIDGE, Mass.–(BUSINESS WIRE)– Aura Biosciences, a clinical-stage biopharmaceutical company developing a novel class of tumor targeted therapies for initial application in primary tumors such as choroidal melanoma, today announced the dosing of the first patient in a...
EO2401 is an innovative, off-the-shelf microbiome-antigen (‘OncoMimic’) based immunotherapy candidate EO2401 combines three ‘OncoMimics’ designed to trigger the immune system into recognizing tumor cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response Clinical trial with EO2401 now underway in two cancer indications: brain cancer (glioblastoma) and adrenal tumors Paris, France and Cambridge, MA,...
Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritis Well-tolerated with comparable safety profile to intravenous ertapenem Spero intends to complete NDA submission for U.S. regulatory approval of tebipenem HBr in the second quarter of 2021 Management to host...
Lundbeckfonden-forsker har stået i spidsen for kortlægning af aktiviteten i 80.000 forskellige hjerneceller, der i dyreforsøg har vist sig at være med til at styre indviklede blodsukkerprocesser. Det kan få betydning for behandling af type 2 diabetes hos mennesker. Forskere verden over reagerede med forbløffelse, da de i 2016 i det højt estimerede videnskabelige tidsskrift...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 24 August 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care...
– MAU868 has the potential to be the first therapeutic to prevent and treat BKVassociated diseases in transplant patients SAN DIEGO – Aug 17, 2020 – Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that the first patient has been dosed...
1 2 3 11

Nyheder

442 vikingeskeletter fik en tur i DNA-maskinen – nu revideres historien om vikingekulturen
16. september 2020
Håb om at kunne kurere type 2 diabetes med indsprøjtning i hjernen
7. september 2020
Maude er blevet den stereotype migræne-patient – men det er ikke helt virkelighedsdækkende
31. juli 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge